Abstract: A novel hybrid cell line, designated T6-1G9, for production of monoclonal antibodies specific for a unique cell surface epitope associated with a wide variety of human lymphomas and leukemias. Hybridoma T6-1G9 was generated by fusing mouse myeloma cells with spleen cells from a BALB/c mouse that was immunized with a human leukemia antigen preparation isolated from the cell membranes of acute lymphoblastic leukemia cells. This invention also provides a method for producing the new monoclonal antibody designated SN7 and to diagnostic procedures using SN7 to detect various leukemias and lymphomas. Also disclosed are methods of using SN7 or reactive fragments of SN7 for the treatment of leukemia-lymphoma patients.
Abstract: A chelated compound of the formula: ##STR1## where R.sub.1 is independently at each occurrence, R.sub.2, ##STR2## R2 is independently at each occurrence hydrogen, lower alkyl, lower alkyl ester, lower alkyl ether, hydroxy or halogen; A is H, Li, Na, Ca+, Mg+ or Zn+; and Mn is trivalent manganese; provided that, at least two and no more than three R.sub.1 radicals are ##STR3## The compound of the invention is particularly suitable for use in a physiologically compatible composition comprising a physiologically compatible liquid carrier for magnetic resonance imaging. The compound is also suitable as a chelate for removal of manganese from a system.The invention also comprises a method for enhanced magnetic imaging of a mammal organism which comprises introducing the composition at a level of from 20 to 200 mg/Kg of body weight into the circulatory system of the organism; and making a magnetic resonance image of at least a portion of said organism at from 30 minutes to 36 hours after said introduction.
Abstract: Offal material, such as shrimp or crab shells, fish offal, etc, is dried to produce a fine-grained base material or additive for use in foodstuffs and animal fodder by subjecting a starting material in a chamber to a turbulent air current which accelerates the material lumps into various paths of movement. Hereby the material lumps continuously collide with each other, thereby constantly exposing new surfaces or rupture. The chamber is supplied with air, having a temperature which partly depends on the temperature of the starting material and partly depends on the comminution rate, in an amount adjusted according to the amount of starting material introduced per time unit. Hereby it is achieved that free water is immediately removed from the exposed surfaces of rupture by evaporation. By exerting a counter-pressure, the material is retained in the chamber until a desired particle size has been achieved.
Abstract: The process of photodynamic therapy (PDT) is conducted by the step of:1) separately encapsulating at least one activation component for said photodynamic therapy process in a liposome;2) injecting a photosensitizer into a human or animal host;3) injecting the liposome encapsulated components systemically into the same human or animal host; and4) heating the site of the tumor to melt the liposome encapsulated components to permit mixing of the activation components.The mixing of the activation components can result in:a) energy transfer to the previously injected photosensitizer;b) emission of light and absorption of said light by the previously injected photosensitizer; andc) direct formation of at least one cytotoxic species that functions against the tumor.The heating of the site of the tumor is accomplished by one of the following methods: laser, ultra sound, radio-frequency or microwave frequency. Photofrin photosensitizer is a preferred photosensitizer.
Abstract: An apparatus for feeding sheet-shaped blanks (9) of deep-drawable synthetic plastic material to the receiving station of a deep-drawing machine having a plurality of suction plates (15) wherein a supply roll (2) holding a web (1) of synthetic plastic material which is capable of being intermittently driven by pairs (3, 4, 23) of drive rollers and moved in front of a cutting means (5) having on its downstream side a magazine (8), a movable flap (11) provided with suckers (33) and a first supporting plate (13) being adapted to be brought into engagement with the removal side of the magazine (8), a second movable supporting plate (16) provided with suckers (33) being disposed on the other side, guide means (35) being provided in order to feed the blanks (9) from the movable flap (11) and round onto the opposite side of the suction plate (15) to the second supporting plate (16).
Type:
Grant
Filed:
August 20, 1992
Date of Patent:
October 12, 1993
Assignee:
Tetra Alfa Holdings S.A.
Inventors:
Wilhelm Reil, Udo Liebram, Manfred Wallich, Bernhard Korus
Abstract: A chelated compound of the formula: ##STR1## where R.sub.1 is independently at each occurrence, ##STR2## R.sub.2 is independently at each occurrence hydrogen, lower alkyl, lower alkyl ester, lower alkyl ether, hydroxy or halogen; A is H, Li, Na, Ca+, Mg+or Zn+; and Mn is trivalent manganese; provided that, at least two and no more than three R.sub.1 radicals are ##STR3## The compound of the invention is particularly suitable for use in a physiologically compatible composition comprising a physiologically compatible liquid carrier for magnetic resonance imaging. The compound is also suitable as a chelate for removal of manganese from a system.The invention also comprises a method for enhanced magnetic imaging of a mammal organism which comprises introducing the composition at a level of from 20 to 200 mg/Kg of body weight into the circulatory system of the organism; and making a magnetic resonance image of at least a portion of said organism at from 30 minutes to 36 hours after said introduction.